Enovis Corporation — FY2022 Form 10-K Summary
Business context and reporting period
Enovis, formerly Colfax Corporation, is a medical technology company focused on orthopedic, reconstructive, rehabilitation, pain-management and physical-therapy products. The fiscal year ended December 31, 2022. Following the April 4, 2022 separation of the fabrication technology business into ESAB Corporation, Enovis operates through Prevention & Recovery and Reconstructive segments.
Enovis distributed 90% of ESAB to shareholders in April 2022 and sold its retained 10% ESAB stake in November 2022 in exchange for $230.5 million of term-loan debt. Prior-period fabrication technology results are presented as discontinued operations.
Key financial metrics
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Net sales | $1,563.1 million | $1,426.2 million | +9.6% |
| Gross profit / margin | $869.4 million / 55.6% | $777.7 million / 54.5% | Margin +110 bps |
| Operating loss / margin | $(71.2) million / (4.6%) | $(62.8) million / (4.4%) | Loss widened |
| Net loss from continuing operations | $(38.2) million | $(102.3) million | Improved |
| Adjusted EBITDA | $236.1 million | $206.0 million | +14.6% |
| Adjusted EBITDA margin | 15.1% | 14.4% | +70 bps |
| Net cash from operating activities | $(55.9) million | $356.1 million | Declined materially |
| Capital expenditures and intangibles | $105.5 million | $104.2 million | Broadly stable |
| Cash and cash equivalents | $24.3 million | $680.3 million | Decreased substantially |
Consolidated net loss attributable to Enovis was $13.3 million, or $0.25 per diluted share, compared with net income of $71.7 million, or $1.40 per diluted share, in 2021. Discontinued operations contributed $26.4 million of after-tax income in 2022, compared with $178.5 million in 2021.
Segment performance
- Prevention & Recovery: Sales were $1,027.6 million, essentially flat with 2021. Adjusted EBITDA increased to $141.3 million from $133.5 million, and the margin increased to 13.8% from 13.0%. Organic growth and pricing largely offset $30.9 million of unfavorable currency translation.
- Reconstructive: Sales increased 33.8% to $535.5 million, driven by acquisitions and 11.8% existing-business growth as elective procedures recovered. Adjusted EBITDA increased to $94.7 million from $72.5 million, although the margin declined to 17.7% from 18.1% because recent acquisitions were initially dilutive.
- Approximately 32% of 2022 sales were generated outside the United States. The U.S. dollar reduced reported sales by approximately $36.0 million compared with 2021.
Material changes versus the prior comparable period
- The ESAB separation materially changed the company’s capital structure, reporting presentation and operating profile. ESAB’s results are classified as discontinued operations for all periods presented.
- Enovis completed four asset acquisitions, two business acquisitions and one investment in 2022. The principal business acquisitions were 360 Med Care and Insight Medical Systems, which added distribution capabilities and the ARVIS augmented-reality surgical-navigation platform.
- Gross margin improved despite inflation in supply-chain, logistics and other costs. Management implemented tactical price increases, principally in Prevention & Recovery.
- Operating expenses increased substantially, including $61.0 million of strategic transaction costs, $31.5 million of stock-based compensation, $19.0 million of restructuring and other charges, and $16.7 million of medical-device-regulation and related costs.
- Reported results included a $102.7 million gain on the ESAB investment exchange, a $36.7 million insurance settlement gain and an $8.8 million gain from remeasuring the prior Insight investment. These items significantly affected GAAP results.
- Working capital was a $116.0 million operating cash use, primarily because inventories increased to protect against supply-chain volatility. Inventory increased to $426.6 million from $356.2 million.
Debt, liquidity and cash flow
- At December 31, 2022, total debt was $259.3 million, consisting primarily of a $219.3 million term loan due April 4, 2023 and $40.0 million drawn on a revolving facility.
- The revolving credit facility has total capacity of $900 million, with $860.0 million available at year-end. Management expected to use the revolver to repay the term loan maturity.
- The weighted-average borrowing rate under the credit agreement was 5.71%. All borrowings were variable-rate facilities based on SOFR, creating interest-rate exposure.
- The company was in compliance with its debt covenants at year-end. Covenants include a maximum total leverage ratio of 4.00:1.00, stepping down to 3.75:1.00 in June 2023 and 3.50:1.00 in June 2024, and a minimum interest-coverage ratio of 3.00:1.00.
- Net cash used in investing activities was $176.4 million, including $73.7 million for acquisitions and investments. Net cash used in financing activities was $465.1 million, reflecting significant debt repayments following the separation.
- Management stated that available liquidity was adequate for operations for the next twelve months and the foreseeable future, but year-end cash was low relative to current liabilities and near-term debt maturities.
Outlook, commentary, risks and unusual items
The filing does not provide a clear formal revenue or earnings guidance range. Management’s stated strategy emphasizes organic growth, acquisitions, new product development, EGX continuous improvement initiatives and margin expansion as acquired businesses mature.
- COVID-19 effects had moderated, but healthcare-provider staffing shortages, reduced procedure capacity, supply-chain disruption, logistics delays and inflation continued to affect demand and costs.
- Key risks include acquisition integration, leverage and refinancing, variable interest rates, foreign exchange, raw-material and labor inflation, supply shortages, competition, reimbursement pressure, regulatory approvals, product liability, recalls, cybersecurity and data privacy.
- European Medical Device Regulation compliance remains a significant operational requirement. The company was working with its notified body to obtain required certifications and recertifications.
- Goodwill totaled approximately $2.0 billion. No impairment was recorded, but estimated fair value exceeded carrying value by only approximately 8% for Reconstructive and 9% for Prevention & Recovery, making the balances sensitive to lower growth, higher discount rates or weaker operating performance.
- Unconditional supplier purchase obligations totaled $162.0 million, most of which was expected to be paid by December 31, 2023. Letters of credit outstanding totaled $7.1 million.
- General litigation was not expected to have a material adverse effect, although the company noted that unfavorable outcomes in substantially all proceedings could be material.
Most important facts for investors to verify
- Verify the refinancing or repayment of the $219.5 million term-loan obligation that matured on April 4, 2023 and its effect on interest expense, leverage and covenant compliance.
- Separate recurring operating performance from the $102.7 million ESAB gain, $36.7 million insurance settlement gain, $8.8 million Insight remeasurement gain and other transaction-related items.
- Assess whether Reconstructive acquisition growth becomes margin-accretive and whether integration costs decline as management expects.
- Monitor operating cash conversion, inventory levels and working-capital requirements after the 2022 cash outflow.
- Evaluate goodwill headroom, reimbursement trends, medical-device regulatory certifications and exposure to product recalls or liability claims.
- Review the effect of foreign exchange, inflation and variable-rate debt on future margins, cash flow and net earnings.